Inmune Bio, Inc.
Ebstrocel™
RDEB
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews Ebstrocel™ for RDEB around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 13h ago
“The Company also intends to use the MHRA feedback to inform future interactions with the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) with additional filings planned in late 2026 or early 2027, subject to ”